Lawson research team working to personalize cancer care

The Lawson Translational Cancer Research Team (LTCRT) of the Lawson Health Research Institute is one of five groups participating in a new study that seeks to personalize cancer drug treatment.

The Genomics Pathway Sequencing (GPS) study, led by the Princess Margaret Hospital in Toronto, will assess the feasibility of identifying specific genetic markers (mutations) in the DNA of patients' tumours. This information will then be used to identify more targeted treatments.

The Lawson team has developed a process for London where they can obtain a fresh tissue sample from the patient's tumour biopsy. This tissue is sent away to a lab in Toronto where two types of DNA analysis are performed. Within three weeks a report on the cancer's is provided to the patient's oncologist. "With this new information, it is hoped the oncologist can deliver a more tailored treatment plan," says Dr. Eric Winquist, lead of the LTCRT and medical oncologist at the London Health Sciences Centre.

Jennifer Malone from London, Ontario was diagnosed with cancer in 2006. Over the next five years, she exhausted all standard cancer treatments. A of her tissue sample identified a mutation in a gene known as KRAS. Fortunately, a study investigating a new drug known to target mutations in KRAS was available at the Princess Margaret Hospital and Jennifer was enrolled.

Since starting the , Jennifer's tumour has regressed and many of her cancer symptoms have improved or disappeared. It is "remarkable and amazing," says Jennifer. "Participating in this study gave me an option where previously no option existed."

While the GPS study is still in early development, the idea of more precisely matching patient treatment to their cancer's individual holds great promise. "We are excited to be discovering what the future holds for our patients using a personalized approach to ," says Dr. Winquist, "and the GPS study is a promising look at what this future may look like."

Provided by Lawson Health Research Institute

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Bone cancer, from the lab to the clinic

Jun 08, 2011

A new study into osteosarcoma - cancer of the bone - will use advances in genomic research and analysis to identify new genes that give rise to the condition and to create personalised blood tests for children and young adults ...

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

Nov 21, 2014

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

Nov 21, 2014

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.